Innovative RNA-Based Therapies Show Promise for Treating Neurological Disorders

Revolutionizing Treatment for Brain Disorders

For many years, researchers have sought improved methods to address severe neurological diseases such as Alzheimer's and Parkinson's. While various treatments have demonstrated potential in laboratory settings, a significant challenge persists: effectively delivering medications to the brain. Dr. Jessica Larsen, an endowed associate professor at Clemson University specializing in chemical and biomolecular engineering, suggests that the future of brain disorder treatment may involve a novel approach—utilizing RNA encapsulated in specially designed nanoparticles instead of directly administering proteins. "RNA is considerably smaller than full-length proteins. Once it enters a cell, it can be translated into the desired protein," explains Larsen.

Challenges in Treating Neurological Disorders

Why Treating Brain Diseases Is So Challenging?

Many neurological conditions stem from issues related to specific proteins. Traditionally, scientists have tried to replace these proteins directly, but this method presents considerable difficulties. "When addressing diseases in the body, they often arise from protein-related problems," Larsen states. "We can either reintroduce the proteins, which is complicated due to their size and difficulty in targeting specific areas in the body."

Innovative Solutions for RNA Delivery

RNA presents an alternative, yet it has its own challenges, particularly its rapid degradation in the bloodstream. "You can't simply inject the RNA you need; it would disintegrate," she notes. To address this, Larsen's laboratory encapsulates RNA within nanoparticles that protect it from breakdown during circulation. These particles can also be tailored to target specific cells, enhancing the likelihood of reaching the desired location. "We encapsulate it in a nanoparticle, safeguarding the RNA from degradation while guiding it to its intended target," Larsen explains.

Navigating the Blood-Brain Barrier

Outsmarting The Brain's Natural Defence System

Another significant challenge is the blood-brain barrier, a protective layer of blood vessels that prevents harmful substances from entering the brain. While this barrier is crucial for safeguarding healthy brain tissue, it also obstructs many potentially beneficial medications. "The brain has this barrier intentionally to shield us from foreign materials," Larsen remarks. She humorously likens the barrier to a well-known fantasy character, stating, "It's almost like, 'You shall not pass,' akin to Gandalf in The Lord of the Rings." Instead of seeking a universal method to breach this barrier, Larsen's team is developing delivery systems tailored to specific diseases. "We adapt our strategy for each condition," she explains. "How can we manipulate this barrier and create our own Trojan horse that convinces the brain it's accepting something beneficial?" This customized approach could enhance the effectiveness of therapies while addressing the underlying biological changes associated with diseases.

Addressing Root Causes of Neurological Disorders

Targeting The Cause - Not Just The Symptoms

Larsen envisions RNA-based therapies evolving beyond mere symptom management. In the case of Parkinson's disease, her research team is exploring methods to restore an enzyme known as tyrosine hydroxylase, which diminishes as the disease progresses. "Imagine if we could provide the RNA that produces tyrosine hydroxylase as needed," she suggests. "This way, we wouldn't just be treating symptoms; we'd be addressing a significant part of the underlying cause," she adds. Similarly, Alzheimer's disease is marked by the accumulation of amyloid-beta plaques in the brain. Larsen points out that researchers have already demonstrated that certain enzymes can aid in breaking down these plaques. Her strategy focuses on delivering RNA that enables brain cells to generate these enzymes autonomously. Although this research is still in its early stages, Larsen acknowledges that scaling production and reducing costs are major hurdles before these therapies can be made available to patients. Nonetheless, this work signifies an exciting advancement toward more precise and personalized treatments that could revolutionize the management of Alzheimer's, Parkinson's, and other neurological disorders.